<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02138734</url>
  </required_header>
  <id_info>
    <org_study_id>CA-ALT-803-01-14</org_study_id>
    <nct_id>NCT02138734</nct_id>
  </id_info>
  <brief_title>QUILT-2.005: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer</brief_title>
  <official_title>A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altor BioScience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altor BioScience</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase Ib/II, open-label, dose-finding, multicenter study of intravesical BCG plus
      ALT-803 in Non-muscle invasive bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety, identify the Maximum Tolerated Dose
      (MTD) of ALT-803 and determine the Recommended Dose (RD) level of ALT-803 combined with BCG
      in patients who have nonmuscle invasive bladder cancer. The anti-tumor activity of
      BCG+ALT-803 will also be assessed. In addition, the study will characterize the molecular,
      immunogenicity and pharmacokinetic profile of BCG+ALT-803.

      The study includes a dose escalation phase (Phase Ib) and an expansion phase (Phase II). The
      dose escalation phase is concluded when the MTD is determined. A dose level (RD) will be
      designated for the phase II study. For the noncomparative randomized phase II, patients will
      be randomized to two treatment arms: either ALT-803 at the RD level in combination with BCG
      (50 mg) or BCG (50 mg) alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Profile</measure>
    <time_frame>48 months</time_frame>
    <description>Number and severity ot treatment related AEs that occur or worsen after the first dose of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD Determination and RD Designation</measure>
    <time_frame>9 months</time_frame>
    <description>Determine the maximum tolerated dose (MTD) and designate the recommended dose (RD) level for Phase II.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit</measure>
    <time_frame>48 months</time_frame>
    <description>Number of patients with an objective, complete response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>48 months</time_frame>
    <description>For phase Ib and II
Area under the plasma concentration-time curve from time zero to infinity (AUC) and the half-life of ALT-803.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>48 months</time_frame>
    <description>Measures the serum and urine levels of IL-2, IL-4, IL-6, IL-10, IFN-gamma and TNF-alpha in treated patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular Alterations</measure>
    <time_frame>48 months</time_frame>
    <description>Measures the molecular changes (angiogenesis, apoptosis and proliferative index) and immune cell infiltration (assessed by immunohistochemistry for immune cells) in treated patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Cell Assessment</measure>
    <time_frame>48 months</time_frame>
    <description>The percentage and numbers of specific immune cell subsets and their phenotypes, including T cells, B cells, and NK cells will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>48 months</time_frame>
    <description>Measures the serum level of anti-ALT-803 in patient samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months</time_frame>
    <description>All enrolled patients will have a cystoscopy and biopsy (if warranted) performed every 3 months for 2 years to determine recurrence-free survival, progression-free survival, overall survival and duration of response.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Non-muscle Invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>BCG+ALT-803 (phase I and II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>for BCG-naive patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCG alone (phase II only)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>for BCG-naive patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG+ALT-803</intervention_name>
    <description>BCG and ALT-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks in phase I and phase II. Phase II includes maintenance treatment consisting of BCG+ALT-803 for 3 consecutive weeks at 3, 6 and 12 months.</description>
    <arm_group_label>BCG+ALT-803 (phase I and II)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG</intervention_name>
    <description>BCG-only will be administered via intravesical instillation weekly for 6 consecutive weeks in phase II. Phase II includes maintenance treatment consisting of BCG for 3 consecutive weeks at 3, 6 and 12 months.</description>
    <arm_group_label>BCG alone (phase II only)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        ENTRY CRITERIA:

        DISEASE CHARACTERISTICS:

          -  Histologic confirmation of non-muscle invasive bladder cancer of the transitional cell
             carcinoma high-risk subtype.

             ◦High risk is defined as any high-grade Ta or T1, CIS.

          -  No evidence of muscle-invasive bladder cancer or regional and/or distant metastasis.

        PRIOR/CONCURRENT THERAPY:

          -  No prior BCG treatment.

          -  No concurrent use of other investigational agents.

        PATIENT CHARACTERISTICS:

        Performance Status • ECOG 0, 1, or 2.

        Bone Marrow Reserve

          -  Absolute neutrophil count (AGC/ANC) ≥ 1,000/uL

          -  Platelets ≥ 100,000/uL

          -  Hemoglobin ≥ 8g/dL

        Renal Function

          -  Glomerular Filtration Rate (GFR) &gt; 40mL/min or serum creatinine ≤ 1.5 x ULN

        Hepatic Function

          -  Total bilirubin ≤ 2.0 X ULN

          -  AST, ALT, ALP ≤ 3.0 X ULN

        Cardiovascular

          -  No symptomatic congestive heart failure &lt; 6 months.

          -  No severe/unstable angina pectoris &lt; 6 months.

          -  No myocardial infarction &lt; 6 months.

          -  No NYHA Class &gt; II.

          -  No marked baseline prolongation of QT/QTc interval.

        Pulmonary

        • Adequate pulmonary function without any clinical sign of severe pulmonary dysfunction.

        Other

          -  Currently eligible for intravesical BCG therapy.

          -  Negative serum pregnancy test if female and of childbearing potential.

          -  No women who are pregnant or nursing.

          -  Subjects, both females and males, with reproductive potential must agree to use
             effective contraceptive measures for the duration of the study.

          -  No known autoimmune disease other than corrected hypothyroidism (for phase Ib only).

          -  No prior organ allograft or allogeneic transplantation (for phase Ib only).

          -  No known positive HIV status.

          -  No history or evidence of uncontrollable CNS disease.

          -  No psychiatric illness/social situation that would limit compliance with study
             requirements.

          -  No other illness that in the opinion of the investigator would exclude the patient
             from participating in this study.

          -  Must provide signed informed consent and HIPPA authorization and agree to comply with
             all protocol-specified procedures and follow-up evaluations.

          -  No active systemic infection requiring parenteral antibiotic therapy.

          -  No ongoing chronic systemic steroid therapy required.

          -  No concurrent febrile illness, active urinary tract infection, active tuberculosis, a
             history of hypotension or anaphylactic reactions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hing C Wong, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Altor BioScience</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralee' Bishop Bunt</last_name>
      <phone>205-934-2272</phone>
      <email>erikabunt@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Nix, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alaska Clinical Research Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Adams, RMA</last_name>
      <phone>907-276-1455</phone>
      <email>LAdams@akmed.com</email>
    </contact>
    <investigator>
      <last_name>William R Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Department of Urology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nazy Zomorodian, NP</last_name>
      <email>nzomorodian@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Karim Chamie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charleen McDaniel</last_name>
      <phone>916-734-5173</phone>
      <email>cmcdaniel@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mark Alger</last_name>
      <email>mwalger@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stanley Yap, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skyline Sherman Oaks</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Gomez</last_name>
      <phone>310-602-5018</phone>
      <email>stacey.gomez@skyuro.com</email>
    </contact>
    <investigator>
      <last_name>Richard David, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skyline Urology</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Gomez</last_name>
      <phone>310-602-5018</phone>
      <email>stacey.gomez@skyuro.com</email>
    </contact>
    <investigator>
      <last_name>Fred Wolk, MD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Connecticut Hematology &amp; Oncology Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Johnson</last_name>
      <phone>860-886-8362</phone>
      <email>drsusanjohnson@cox.net</email>
    </contact>
    <contact_backup>
      <last_name>Nancy Wilcox</last_name>
      <phone>860-886-8362</phone>
      <email>nwilcox@echoct.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dennis E Slater, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cortlin Croft</last_name>
      <phone>813-745-7559</phone>
      <email>Cortlin.Croft@Moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Wade Sexton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Hawaii Cancer Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isobel Webster</last_name>
      <phone>808-564-5805</phone>
      <email>iwebster@cc.hawaii.edu</email>
    </contact>
    <investigator>
      <last_name>Charles J Rosser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Hopkins</last_name>
      <phone>913-588-2566</phone>
      <email>Chopkins2@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Holzbeierlein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Dimovski</last_name>
      <phone>313-576-9771</phone>
      <email>dimovskt@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Michael L Cher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darcie l Findley</last_name>
      <phone>603-650-4595</phone>
      <email>Darcie.L.Findley@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Einar F Sverrisson, MB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlin Kosinski, MS</last_name>
      <phone>516-535-1900</phone>
      <email>KKosinski@Winthrop.org</email>
    </contact>
    <investigator>
      <last_name>Aaron E Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Eitman</last_name>
      <phone>216-844-5393</phone>
      <email>cheryl.eitman2@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Hoimes, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandria z Lahdya</last_name>
      <phone>206-598-0853</phone>
      <email>azlahdya@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan L Wright, MD, MS, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2014</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antitumor</keyword>
  <keyword>BCG</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>cancer</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>instillation</keyword>
  <keyword>interleukin-15</keyword>
  <keyword>intravesical</keyword>
  <keyword>naive</keyword>
  <keyword>non-muscle invasive</keyword>
  <keyword>transitional cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

